# Rahko

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rahko

- Industry: Software
- Headquarters: London, UK
- Website: www.rahko.ai
- Total disclosed funding: $1.6M
- Latest round: Seed (Jun 20, 2019)
- Investors on record: 1

## About

Rahko is a pioneering company specializing in quantum machine learning solutions aimed at enhancing chemical simulations for various industries, particularly pharmaceuticals and materials science.Rahko provides advanced quantum machine learning platforms focused on quantum chemistry. Founded in London, UK, it was acquired by Odyssey Therapeutics Inc. in January 2022 from Balderton Capital for an undisclosed amount. The firm has engaged in two notable deals, with the most recent funding round being a Seed round that raised GBP 1.280 mn, leading to a current valuation of GBP 6.121 mn.Rahko specializes in quantum machine learning solutions tailored for quantum chemistry applications. Their primary offering is a quantum machine learning platform that integrates advanced algorithms designed to enhance chemical simulations and facilitate complex molecular analyses. This platform targets commercially viable challenges for industries relying on precise chemical modeling, such as pharmaceuticals and materials science. Rahko collaborates with leading quantum hardware manufacturers, focusing on B2B partnerships with large enterprises that require sophisticated computational tools. Their solutions are utilized globally by major clients in technology and pharmaceutical sectors, primarily across North America and Europe.In the most recent fiscal year of 2022, Rahko reported a revenue of GBP 3,705,373.10 and an EBITDA of GBP 356,259.90. Their revenue model is based on B2B partnerships and collaborative projects with significant players in the quantum hardware and chemical industries, derived from subscription agreements, project-based contracts, or joint ventures.Following the acquisition by Odyssey Therapeutics Inc., Rahko is expected to enhance its offerings by integrating artificial intelligence and physics-based methods into drug development processes. This strategic move aligns with Odyssey's aim to leverage master drug-hunters to elevate precision medicine. Plans for expanding into new markets are anticipated, although specific geographic regions and timelines for those expansions have not been disclosed. The recent Seed funding will support these initiatives and facilitate the development of new products aimed at solving complex challenges in the chemical simulation landscape.

## Funding rounds

- Seed, Jun 20, 2019, $1.6M — Balderton Capital

## Investors

- Balderton Capital (https://capitalatlas.ai/funds/balderton-capital) — Seed